Cannabis
Delic Partnership with Paradigm Healthcare of Georgia Brings Clinically Relevant Toxicology Testing to Ketamine Treatment for First Time
Delic Holding Corp Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness platform, today announced a first of its kind partnership with Paradigm Healthcare, an independent clinical laboratory located in St. Simons, Georgia, United States, with a focus on high complexity, clinical toxicology, to bring state-of-the-art testing to Ketamine Infusion Centers LLC (“KIC“). Through the partnership, KIC will have access to Paradigm’s Benchmark UDT™ toxicology solution that uses LC/MS/MS test methods to identify and accurately measure drug compounds in the body, ensuring the highest quality toxicology results and clinically relevant test data to support medical decision-making.
The addition of Paradigm’s innovative Benchmark UDT™ test platform gives KIC the ability to:
- Identify any type of drug that may already be present in a patient’s system to avoid potential conflicts with ketamine infusion and to ensure patient safety before ketamine treatment is started.
- Detect very high levels of ketamine and norketamine, thereby enabling KIC clinicians to make patient-specific treatment decisions and to ensure proper ketamine levels are maintained throughout infusion treatment.
- Compare ketamine and norketamine levels with analytical data captured from Clinifusion EMR, including benchmarks when treatment started and ended, at what point patients began getting better, and the number of times the patient visited the clinics for treatments, to provide the best overview of a patient’s treatment journey.
Matt Stang, founder and CEO of DELIC stated, “Paradigm’s Benchmark testing platform brings state-of-the-art drug testing technology and new reporting tools to clinicians who use psychedelics to treat people with serious behavioral health conditions. We are proud to partner with Paradigm. By integrating their state-of-the-art testing capabilities, KIC will be able to provide patients suffering from depression, anxiety, PTSD and other debilitating conditions the most accurate, personalized ketamine treatment protocol in the industry.”
“We believe this partnership with Paradigm will take patient care to the next level,” said Sonny Diaz, co-founder of KIC. “Their powerful toxicology testing gives us the ability to quickly assess a patient’s system ahead of treatment and develop a custom plan for moving them through the protocol. Paired with data from Clinifusion EMR, we can see exactly when they started to get better and can keep people at the right levels to maintain their wellness. KIC will be the only clinic able to aggregate this type of analytical data and validate the results.”
Catherine Veal, President, Paradigm stated, “We are very excited about this partnership with Delic and KIC. Paradigm is committed to providing the best scientific data available to support KIC and Delic in their efforts to combine laboratory science with the developing science of psychedelic treatments in patient care. Our industry-leading toxicology testing will now be available to help people who struggle with different behavioral health conditions, including PTSD, major depression, anxiety, as they undergo ketamine infusion to find their way back to better health and wellness.”
KIC enables Delic to leverage its central hub of psychedelic education, media, and information sources to patients seeking psychedelic therapy. Delic Corp is uniquely positioned to bring digital awareness to its various holdings under the Delic Corp umbrella, and drive online users to brick and mortar holdings, including KIC’s physical psychedelic clinics.
Over the last 3 years, KIC has expanded from Arizona to California, while overseeing 4,000 treatments delivered to date, and generating over USD$1.5MM in revenue. KIC operates under the Delic Corp umbrella, under the direction and guidance of Diaz, Dr. Christopher Ray, Rogelio Monzon, and Ganesh Acharya.
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis2 weeks ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
transfer2 weeks ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf1 week ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE1 day ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET